Egis Gyogyszergyar Rt.

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Richter Gedeon Vegyeszeti Gyar Rt

Egis Gyogyszergyar Zrt.

Other

Les Laboratoires Servier

Orion Corporation

Egis Gyogyszergyar Nyrt

Egis Gyogyszergyar

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Hyogyszergyar Nyrt.

Egis Pharmaceutical

Gis Gyogyszergyar Rt.

Egis Gyoyszergyar Rt

Gyula Simig

Tibor Mezei

Gabor Blasko

Jozsef Barkoczy

Istvan Gacsalyi

Kalman Nagy

József Barkóczy

Andras Egyed

Gabor Gigler

Ferenc Lorant Bartha

Katalin Szemeredi

Gábor Szénási

Zoltan Budai

Balazs Volk

Jozsef Fetter

Gyula Hornyak

Karoly Lempert

György Lévay

Karoly Zauer

Gabor Doleschall

Marton Fekete

Istvan Gyertyan

Balázs Volk

Márta Porcs-Makkay

Jozsef Nyitrai

Katalin Pallagi

Péter Kótay Nagy

István Gacsályi

Kalman Harsanyi

Klara Reiter Nee Esses

Kálmán Nagy

Zoltán Greff

László Szlávik

Adrienn Keszthelyi

Krisztina Móricz

András Egyed

László Gábor Hársing

Jozsef Reiter

Daniel Bozsing

Pal Vago

Györgyi Vereczkeyné Donáth

Éva Schmidt

Andras Bilkei-Gorzo

Karoly Tihanyi

Gábor Gigler

K&aacute;roly Tihanyi

Andr&aacute;s Egyed

Gábor Berecz

J&aacute;nos Szul&aacute;gyi

Norbert N&eacute;meth

M&aacute;rta Porcs-Makkay

Gyuláné Körtvélyessy

Zolt&aacute;n Budai

Lujza E Petocz

Attila Mandi

Eniko Szirt Nee Kiszelly

Gabor Nemeth

Zoltán Varga

Eva Schmidt

Istvan Ling

Gábor Németh

Gyula Lukacs

Péter Trinka

Gyorgy Krasznai

Margit Csorgo

Gyula Lukács

Enikó Molnár

Zsuzsanna Szent-Királlyi

Janos Imre

Eva Sipos

Gyorgy Ruzsics

András Mravik

Mátyás Milen

János Wellmann

Bálint Nyulasi

Csaba Szantay

Gabor Kovacs

Imre Moravcsik

Laszlo Balazs

Ferenc Andrasi

Tibor Szabo

Tamas Hamori

Katalin Grasser

Pal Berzsenyi

Imre Klebovich

Gabor Zolyomi

Laszlo Pongo

Peter Tompe

Maria Szecsey Nee Hegedus

Lajos Novak

Andras Dancso

Gyorgyi Kovanyine Lax

Eszter Szentkuti

Maria Tothne Lauritz

Eva Furdyga

Laszlo Gaal

Anna Bakonyi

Katalin Horvath

János Szulágyi

Tamás Gregor

The present invention relates a new process for the preparation of ozanimod of the formula and acid addition salts, via new intermediates and a new polimop form of ozanimod base.

Process for the production of ozanimod

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X=I, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Method for the production of lumateperone and its salts

Compounds of formula (I) having a selective dual action on the central GABAergic system, and a process for their preparation and to pharmaceutical compositions containing them.

Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and isolating the thus obtained rosuvastatin zinc salt (2:1). 

Rosuvastatin zinc salt

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

The invention relates the use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or pharmaceutically acceptable salts thereof for the preparation of medicaments suitable for the improvement of cognitive function or obtaining neuroprotective effect. The medicaments containing 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazol-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or therapeutically acceptable salt thereof can be used for the treatment or prevention of neuronal death, mental decline, sclerosis multiplex, Creuzfeld-Jacobs disease, Huntington-syndrome, amyotrophic lateral sclerosis, Parkinson-disease, memory disturbance, loss of memory, amnesia, stroke or for the improvement of memory function or learning ability.

Medicament for the enhancement of cognitive function and neuroprotection

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The invention relates to new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula &#x2014;NH&#x2014;R', wherein R&#x2032; stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof. The invention also encompasses a process for the preparation of said compounds, pharmaceutical compositions containing them and new intermediates useful for the preparation of the new 8-chloro-2,3-benzodiazepine derivatives. The compounds according to the invention possess AMPA/kainate receptor inhibiting activity. 

8-chloro-2,3-benzodiazepine derivatives

The compounds of the general Formula (I), wherein Ris aryl or alkyl; Rrepresents alkyl; Rrepresents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (IV) (wherein the definitions of Rand Rare as above), with at least 2 molar equivalents of the compound of the general Formula (VI) (wherein X represents halogen or tertiary butyloxycarbonyloxy group and Ris as defined above). The known compounds of the general Formula (II) (wherein Rand Rare as defined above) are prepared by reacting the compounds of the general Formula (I) with thionyl chloride. The compounds of the general Formula (I) are new intermediates useful in the synthesis of pharmaceutically active ingredients, particularly in the preparation of ACE-inhibitors, e.g. enalapril, perindopril or ramipril.

Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof

The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.

Polymorphs of olanzapine hydrochloride

The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favorable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cadiovascular system. 

Piperazine derivatives of alkyl oxindoles

Growing community of inventors

Budapest, Hungary

Gyula Simig